NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Edge Therapeutics, Inc. (“Edge Therapeutics” or the “Company”) (NASDAQGS: EDGE) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/EDGE-Info-Request-Form-1889. There is no cost or obligation to you.
On March 28, 2018, Edge Therapeutics disclosed “that a pre-specified interim analysis on data from the Day 90 visit of the first 210 subjects randomized and treated in the Phase 3 NEWTON 2 study of EG-1962 demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the study’s primary endpoint, if the study is fully enrolled.” As a result, the Data Monitoring Committee “recommended that the study be stopped based on its conclusion that the study has a low probability of meeting its primary endpoint.” Based on the DMC recommendation, Edge Therapeutics decided to discontinue the Phase 3 NEWTON 2 study. Upon this news, shares of Edge Therapeutics fell from a close of $15.59 on March 27, 2018, to a close of $1.31 per share on March 28, 2018.
To learn more about the investigation of Edge Therapeutics contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/EDGE-Info-Request-Form-1889.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
